Anna Purdum
About Anna Purdum
Anna Purdum serves as the Executive Director of Global Market Access, HEOR & Pricing at Kite Pharma, where she focuses on rare diseases, cell therapies, and oncology. With a robust background in health economics and outcomes research, she has held various leadership roles in the pharmaceutical industry since the 1990s.
Work at Kite Pharma
Anna Purdum has been with Kite Pharma since 2016, currently serving as the Executive Director of Global Market Access, HEOR & Pricing since 2020. In this role, she oversees the Global Health Economics & Outcomes Research team and focuses on developing value strategies and evidence generation for cell therapies. Prior to her current position, she held roles such as Senior Director of HEOR and Interim VP of Market Access. Her extensive experience at Kite Pharma includes launching hematology and oncology products on a global scale.
Education and Expertise
Anna Purdum holds a PharmD from the University of Illinois Chicago, where she studied from 1995 to 1998. She also earned a BS from Drake University between 1984 and 1989 and a Master's degree in Health Economics & Policy from the University of Southern California from 1998 to 2000. Her educational background supports her expertise in health economics, market access, and pricing strategies, particularly in the context of rare diseases and oncology.
Background
Before joining Kite Pharma, Anna Purdum accumulated diverse experience in the pharmaceutical industry. She worked at Bristol-Myers Squibb as the Director of US Health Economics and Outcomes Research from 2012 to 2016. Her career also includes roles at Genentech, where she served as a Senior Medical Science Liaison in Oncology and as a National Managed Care Liaison. Additionally, she has experience in project management from her time at Protocare Sciences and outcomes research at Pharmacia/Pfizer.
Achievements
Throughout her career, Anna Purdum has demonstrated a strong focus on strategic planning and tactical execution in market access and pricing. She has played a significant role in launching hematology and oncology products on a global scale. Her therapeutic interests include rare diseases, cell therapies, and oncology, which align with her responsibilities at Kite Pharma. Anna's leadership in health economics and outcomes research has contributed to the development of value strategies in the pharmaceutical sector.